NASDAQ:FGEN - FibroGen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$58.85 -0.25 (-0.42 %)
(As of 06/18/2018 01:42 AM ET)
Previous Close$58.85
Today's Range$58.0510 - $59.6160
52-Week Range$28.50 - $63.00
Volume1.18 million shs
Average Volume416,468 shs
Market Capitalization$4.92 billion
P/E Ratio-34.02
Dividend YieldN/A
Beta1.95

About FibroGen (NASDAQ:FGEN)

FibroGen logoFibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FGEN
CUSIPN/A
Phone415-978-1200

Debt

Debt-to-Equity Ratio0.19
Current Ratio8.61
Quick Ratio8.61

Price-To-Earnings

Trailing P/E Ratio-34.02
Forward P/E Ratio-37.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$125.67 million
Price / Sales39.11
Cash FlowN/A
Price / CashN/A
Book Value$7.09 per share
Price / Book8.30

Profitability

EPS (Most Recent Fiscal Year)($1.73)
Net Income$-126,200,000.00
Net Margins-102.86%
Return on Equity-27.70%
Return on Assets-16.78%

Miscellaneous

Employees423
Outstanding Shares83,520,000

FibroGen (NASDAQ:FGEN) Frequently Asked Questions

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen Inc (NASDAQ:FGEN) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.01. The biopharmaceutical company had revenue of $31.90 million for the quarter, compared to the consensus estimate of $29.07 million. FibroGen had a negative net margin of 102.86% and a negative return on equity of 27.70%. The company's quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.48) earnings per share. View FibroGen's Earnings History.

When is FibroGen's next earnings date?

FibroGen is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for FibroGen.

What price target have analysts set for FGEN?

7 equities research analysts have issued 1 year price objectives for FibroGen's shares. Their forecasts range from $31.00 to $88.00. On average, they expect FibroGen's share price to reach $66.6667 in the next twelve months. View Analyst Ratings for FibroGen.

What are Wall Street analysts saying about FibroGen stock?

Here are some recent quotes from research analysts about FibroGen stock:
  • 1. According to Zacks Investment Research, "FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California. " (6/15/2018)
  • 2. Mizuho analysts commented, "We expect to see top-line phase 3 data from Disease (CKD) in 4Q18 and a potential regulatory approval in China is expected by year-end 2018. We upgrade to Buy and maintain our $61 PT as we believe the company is likely to gain the first approval in new generation anemia drugs. If Pamrevlumab reproduces its Phase II results in the planned Phase III trial, we see significant upside." (5/15/2018)

Who are some of FibroGen's key competitors?

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:
  • Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 64)
  • Mr. Pat Cotroneo, Chief Financial Officer (Age 54)
  • Dr. K. Peony Yu, Chief Medical Officer (Age 56)
  • Mr. Julian N. Stern, Sec. (Age 93)
  • Dr. Barry A. Berkowitz, Founder

When did FibroGen IPO?

(FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Has FibroGen been receiving favorable news coverage?

Media stories about FGEN stock have trended positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. FibroGen earned a media sentiment score of 0.27 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 47.97 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are FibroGen's major shareholders?

FibroGen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.09%), Farallon Capital Management LLC (2.06%), JPMorgan Chase & Co. (1.16%), Northern Trust Corp (1.00%), Eagle Asset Management Inc. (0.98%) and Lord Abbett & CO. LLC (0.69%). Company insiders that own FibroGen stock include Gerald Lema, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

Which major investors are selling FibroGen stock?

FGEN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Sphera Funds Management LTD., Citigroup Inc., Nexthera Capital LP, Wells Fargo & Company MN, Pinnacle Associates Ltd. and Dimensional Fund Advisors LP. Company insiders that have sold FibroGen company stock in the last year include Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff and Thomas F Kearns Jr. View Insider Buying and Selling for FibroGen.

Which major investors are buying FibroGen stock?

FGEN stock was acquired by a variety of institutional investors in the last quarter, including PointState Capital LP, Artal Group S.A., UBS Group AG, Amundi Pioneer Asset Management Inc., Lord Abbett & CO. LLC, BNP Paribas Arbitrage SA, Millennium Management LLC and Prudential Financial Inc.. View Insider Buying and Selling for FibroGen.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $58.85.

How big of a company is FibroGen?

FibroGen has a market capitalization of $4.92 billion and generates $125.67 million in revenue each year. The biopharmaceutical company earns $-126,200,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. FibroGen employs 423 workers across the globe.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]


MarketBeat Community Rating for FibroGen (FGEN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  325
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.